Sulpiride is mainly excreted unchanged in urine and feces. Does not inhibit CYP 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4. No clinical reports of CYP-related drug-drug interactions.

Sulpiride is a substituted benzamide.

Sulpiride is a conventional antipsychotic used in the treatment of psychoses such as schizophrenia. It has also been given in the management of Tourettes syndrome, anxiety disorders, depression, vertigo, and benign peptic ulceration. Administered orally or as an intramuscular injection.

Sulpiride is about 40% bound to plasma proteins and is reported to have a plasma half-life of about 8 to 9 hours. After intravenous administration of sulpiride, 70% of the dose is recovered as unchanged drug in urine, as compared to 15% after oral administration, and the bioavailability of the oral form is 25—36%. After oral dosing of 14C-labeled sulpiride, urinary excretion of radioactivity was 27—52%, and more than 95% of the radioactivity recovered in the urine and feces is unchanged sulpiride. Sulpiride did not inhibit human CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at 500 mM concentration, which is 8-fold higher than the predicted free fractions (Niwa, 2005). Additionally, there are no clinical reports that sulpiride increases the blood concentrations of other CYP metabolized drugs.

Uneventful use reported in 1 patient with acute porphyria.